APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.
The purpose of this study was to investigate the change in plasma protein expression in first episode schizophrenia after an 8-week treatment with risperidone, and to explore potential biomarkers for metabolic side effects associated with risperidone treatment. Eighty first-episode schizophrenia patientswere enrolled in the study. Fifteen of the 80 patients were randomly selected to undergo proteomic analysis. Plasma proteins were obtained before and after the 8-week risperidone treatment, and measured using two-dimensional gel electrophoresis (2-DE), Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry(MALDI-TOF/TOF) and peptide mass fingerprinting.Proteins with the highest fold changes after risperidone treatment were then measured for all 80 patients using enzyme linked immunosorbent assay (ELISA). The relationship between changes in plasma protein levels and changes in metabolic parameters after risperidone treatment was examined. In 15 randomly selected patients, approximately 1,500 protein spots were detected in each gel by 2-DE. Of those proteins, 22 spots showed significant difference in abundance after risperidone treatment (p's<0.05). After MALDI-TOF peptide mass fingerprinting, apolipoprotein A-I (APOA-I) and Guanine Nucleotide Binding Protein, Alpha Stimulating (GNAS), were found to have the highest fold changes.The content of APOA-I was significantly increased, and the content of GNAS was significantly decreased after risperidone treatment (p's<0.05). The analysis in the entire study sample showed similar findings in changes of APOA-I and GNAS after risperidone treatment. Further analysis showed significant relationships between changesin APOA-1 and changes in triglyceride, total cholesterol, and body mass index after controlling for age, gender and family history of diabetes. Similar analysis showed a trend positive relationship between changes in GNAS and changes in BMI. Using proteomic analysis, the study suggested that APOA-I might be a novel biomarkers related to metabolic side effects in first episode schizophrenia treated with risperidone.
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China; University of Massachusetts Medical School UMass Memorial Medical Center, Worcester, Massachusetts, United States of America.
Xueqin
X
Song
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xue
X
Li
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jinsong
J
Gao
The Mental Health Institute of the Second Xiangya Hospital,Central South University, Changsha, Hunan, China.
Jingping
J
Zhao
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Youhui
Y
Li
University of Massachusetts Medical School UMass Memorial Medical Center, Worcester, Massachusetts, United States of America.
Xiaoduo
X
Fan
Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China; Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Luxian
L
Lv
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002864:Chromogranins; D005260:Female; D019205:GTP-Binding Protein alpha Subunits, Gs / Q000097:blood; D006801:Humans; D008297:Male; D040901:Proteomics; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D055815:Young Adult
D014150:Antipsychotic Agents; D016632:Apolipoprotein A-I; D015415:Biomarkers; D002864:Chromogranins; C406732:GNAS protein, human; D019205:GTP-Binding Protein alpha Subunits, Gs; D018967:Risperidone